Horizon Pharma Inc. (NASDAQ:HZNP) shot up 2% during mid-day trading on Tuesday . The company traded as high as $20.03 and last traded at $19.26, with a volume of 4,419,438 shares changing hands. The stock had previously closed at $18.89.

A number of brokerages have recently issued reports on HZNP. Citigroup Inc. began coverage on shares of Horizon Pharma in a research note on Wednesday, June 1st. They issued a “neutral” rating for the company. Zacks Investment Research upgraded shares of Horizon Pharma from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a report on Monday, July 11th. Piper Jaffray Cos. reiterated a “buy” rating and set a $44.00 price target on shares of Horizon Pharma in a report on Wednesday, April 13th. Vetr upgraded shares of Horizon Pharma from a “hold” rating to a “buy” rating and set a $19.82 price target for the company in a report on Tuesday, June 7th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $29.00 price target on shares of Horizon Pharma in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Horizon Pharma has a consensus rating of “Buy” and an average price target of $28.46.

The firm has a market capitalization of $3.21 billion and a P/E ratio of 259.74. The stock has a 50-day moving average of $18.03 and a 200 day moving average of $16.96.

Horizon Pharma (NASDAQ:HZNP) last posted its earnings results on Monday, May 9th. The biopharmaceutical company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.30 by $0.04. During the same period last year, the business posted $0.18 earnings per share. The business earned $204.70 million during the quarter, compared to analysts’ expectations of $197.73 million. The company’s revenue for the quarter was up 80.9% compared to the same quarter last year. Equities research analysts anticipate that Horizon Pharma Inc. will post $2.35 earnings per share for the current year.

In other Horizon Pharma news, Director Virinder Nohria sold 25,000 shares of Horizon Pharma stock in a transaction on Wednesday, June 15th. The shares were sold at an average price of $17.69, for a total transaction of $442,250.00. Following the completion of the transaction, the director now directly owns 189,836 shares of the company’s stock, valued at $3,358,198.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jeffrey W. Sherman sold 2,900 shares of Horizon Pharma stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $20.00, for a total transaction of $58,000.00. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently bought and sold shares of the company. Deere & Co. purchased a new position in Horizon Pharma during the fourth quarter valued at approximately $1,873,000. Airain ltd purchased a new position in Horizon Pharma during the fourth quarter valued at approximately $2,123,000. Redwood Investments LLC raised its position in Horizon Pharma by 43.8% in the fourth quarter. Redwood Investments LLC now owns 111,682 shares of the biopharmaceutical company’s stock valued at $2,420,000 after buying an additional 34,008 shares during the last quarter. Systematic Financial Management LP raised its position in Horizon Pharma by 100.4% in the fourth quarter. Systematic Financial Management LP now owns 152,340 shares of the biopharmaceutical company’s stock valued at $3,301,000 after buying an additional 76,335 shares during the last quarter. Finally, Zweig DiMenna Associates LLC raised its position in Horizon Pharma by 1,466.9% in the fourth quarter. Zweig DiMenna Associates LLC now owns 433,250 shares of the biopharmaceutical company’s stock valued at $9,389,000 after buying an additional 405,600 shares during the last quarter.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.